Regina Margaret Graul - 05 Aug 2024 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: CYCN
Reported as of: 05 Aug 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2024, 16:05:04 UTC
Prior SEC filing: 26 Jan 2024
Next SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Regina M. Graul

Key filing fact

Regina Margaret Graul filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 07 Aug 2024.

Key facts

This page summarizes Regina Margaret Graul's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2024, 16:05.

Change

Previous filing in this sequence was filed on 26 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYCN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +55,849
Change %
Price: $0.000000
Shares after: 55,849
Date: 05 Aug 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,849
Exercise price: $3.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person was granted an option to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 55,849 shares vest ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remains employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC remarks

President and Chief Executive Officer